Lyell Q1 net loss widens to $68.1M; cash $838M; LYL797 trial starts

Lyell Immunopharma, Inc.

2022-Q1 EPS reported -$0.28 revenue$553,000

GAAP net loss $68.1M vs $55.0M YoY; non-GAAP net loss $50.0M vs $32.3M.
Cash, equivalents and marketable securities $838M as of March 31, 2022.
Phase 1 screening started for LYL797 (ROR1 CAR-T) in TNBC/NSCLC; initial data in 2023.
IND cleared for LYL132 (TCR therapy targeting NY-ESO-1); LYL845 TIL IND on track for H2 2022.
Appointed Gary Lee, Ph.D., as Chief Scientific Officer to lead research strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.